GlassScriptPhysician profile
Syed B Sadiq
NPI 1639309685
$2,378.69
in general payments reported to CMS, 2019-2025
24 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $15.50 · 2021: $156 · 2022: $251 · 2023: $433 · 2024: $337 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $530.13 | 2022-2025 | Xcopri |
| Abbvie INC. | $395.37 | 2021-2025 | Ubrelvy, Qulipta |
| Wenzel Spine, INC. | $238.39 | 2025 | Varilift |
| Biogen, INC. | $219.06 | 2021-2024 | Vumerity, Avonex |
| Livanova USA, INC. | $198.08 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Avanir Pharmaceuticals, INC. | $124.99 | 2019 | |
| Neurocrine Biosciences, INC. | $120.70 | 2022-2025 | |
| Eisai INC. | $109.32 | 2023-2024 | |
| Janssen Biotech, INC. | $52.99 | 2022-2025 | Tremfya |
| Teva Pharmaceuticals USA, INC. | $52.08 | 2021-2025 | Austedo Xr |
| Ge Healthcare | $38.23 | 2021 | |
| Ucb, INC. | $35.28 | 2025 | Rystiggo |
| Nevro Corp. | $34.18 | 2024 | Senza |
| Biotronik Nro, INC. | $29.43 | 2025 | Prospera |
| Ani Pharmaceuticals, INC. | $27.57 | 2025 | Purified Cortrophin Gel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aucta Pharmaceuticals, INC. | $26.77 | 2024-2025 | Motpoly Xr |
| Amneal Pharmaceuticals LLC | $26.26 | 2025 | Crexont |
| C2n Diagnostics, LLC | $23.07 | 2025 | Precivityad2 |
| Boston Scientific Corporation | $21.21 | 2025 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $18.52 | 2025 | Amyvid, Kisunla |
| Janssen Pharmaceuticals, INC | $16.49 | 2022 | |
| Avion Pharmaceuticals | $16.26 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.50 | 2020 | |
| Insightec,INC | $8.81 | 2024 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Sadiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.